Coincidentally enough, I, too, have been diagnosed as a Gleason 10 with the signet ring cell variant. In July 2016. I am sorry that your husband has been similarly diagnosed, but that is not meant to suggest that the outlook is dire for him -- or me. I think much will depend on the pathology reports after the surgery, on evidence of metastasis, and on the PSA scores to come over a period of months and years.
Important: Don't let others' uninformed fears or assumptions of poor prognosis infect your own thinking. Remember, there have been so few rigorous studies about
this variant that no standards of care have evolved for it, at least to my knowledge.
I do know that the prevailing advice is to throw everything you can at it, to aggressively use the strongest, biggest guns: surgery and radiation and drugs. If you choose that route, please take time to assess the impact on quality of life such an approach might have. Others, including your doctors, will be focused primarily, and understandably, on quantity of life, but with no Level One studies to guide them on how best to maximize quantity of life when treating PCa with the signet ring cell variant.
I am not/not suggesting you use quality of life as the determinant of treatment. But I am suggesting you include it on your list of things to think about
. There might be a treatment course you and your doctors like that preserves and protects quality of life better than another course.
I think your move to find someone who specializes in rare forms of PCa is an excellent idea, exactly the right thing to do. I chose a different treatment route than your husband as my profile indicates. But that is not to say I chose a better treatment. Who knows for sure? Only time will tell. My best to you and your husband. Good luck.
69; Dx 4/21/16; Tx pt. 1: 8/16/16: focal cryo+immunotherapy
-- baseline PSA: 5.6
-- GL 6 to 10 (w/signet ring-cell pattern); mapping biopsy on 7/21/16; ECE-; SVI-; LN-
-- bone scan clean, Fluorine PET also clean (7/7/16)
-- CTC score: zero (6/16/16); Decipher: 0.56 (intermediate risk)
-- PSA on 10/17/16 (2 mos. post-Tx): 1.5; PSA 11/17/16: 2.0
-- Tx pt 2: 12/2/16: Focal Cryo+IRE; PSA 1/3/17: 0.8
Post Edited (Boon1) : 1/21/2017 12:02:01 PM (GMT-7)